[Lead compound optimization strategy (2)--structure optimization strategy for reducing toxicity risks in drug...

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Toxicology

Background:

• Idiosyncratic adverse drug reactions (IDR) pose significant risks, leading to severe complications or death.
• Reactive metabolites (RM), formed from alert structures in drugs, are a primary cause of IDR.
• Minimizing RM formation through structural modification is crucial in drug design to reduce toxicity.

Purpose of the Study:

• To review recent methodologies for optimizing drug candidate structures.
• To focus on strategies that reduce toxicity risks associated with reactive metabolites.
• To provide an overview of structure-based approaches for safer drug development.

Main Methods:

• Summarizing recent advancements in structure optimization strategies.
• Analyzing methods to block or alter metabolic pathways of drug candidates.
• Reviewing techniques such as bioisosterism and prodrug design.

Main Results:

• Identified key strategies for reducing drug-induced toxicity.
• Highlighted the importance of understanding metabolic pathways in drug design.
• Demonstrated the effectiveness of structural modifications in mitigating IDR risks.

Conclusions:

• Structure optimization is an effective approach to reduce drug candidate toxicity.
• Targeting alert structures and their metabolism can prevent idiosyncratic adverse drug reactions.
• Implementing these strategies enhances the safety profile of potential therapeutics.